Lymphotoxin alpha-1 beta-2 heterotrimer (LTα1β2) (LTα1β2)

Lymphotoxin alpha (LTα), a member of the tumor necrosis factor (TNF) superfamily, exists as a cell-surface heterotrimer when complexed with lymphotoxin beta (LTβ) in a 1:2 ratio (LTα1β2) (UniProt P01374, Q06643). This membrane-bound form is primarily expressed on activated T, B, and natural killer cells and serves as the specific ligand for the lymphotoxin beta receptor (LTβR) (Gommerman & Browning, 2003). The interaction between LTα1β2 and LTβR is fundamental for the development and maintenance of secondary lymphoid organs and the regulation of immune responses through the induction of chemokines like CXCL13 and CCL21 (Ware, 2005). Pathologically, overactivation of this pathway contributes to chronic inflammation, the formation of tertiary lymphoid structures in autoimmune diseases, and the progression of certain malignancies (Annual Review of Immunology, 2005). Therapeutic agents such as baminercept (a LTβR-Ig fusion protein) and pateclizumab (an anti-LTα antibody) have been developed to block this axis for treating conditions like rheumatoid arthritis and Sjögren's syndrome (ClinicalTrials.gov NCT00432588). While effective in modulating immune architecture, targeting this complex requires careful monitoring due to potential risks of immunosuppression and altered lymphoid tissue integrity.

Other names

Membrane-bound lymphotoxinLT-alpha/beta complexTNF-beta/LT-beta heterotrimerLT-alpha1-beta2Surface lymphotoxin

Neutralization of the LTα1β2 heterotrimer to prevent binding and activation of the Lymphotoxin beta receptor (LTβR), thereby inhibiting downstream pro-inflammatory signaling and lymphoid tissue maintenance (Gommerman & Browning, 2003; Ware, 2005).